News

Activation Capital Announces Plans for Development of Innovation Center – A New Life Sciences Center at Bio+Tech Park

Activation Capital, an innovation ecosystem development organization, announced plans to develop the 102,000-square foot Innovation Center in the Bio+Tech Park in Richmond, Virginia.

The 34-acre Bio+Tech Park is a commercial life sciences hub in downtown Richmond adjacent to the VCU Medical Center at Virginia Commonwealth University, and is home to over 70 companies, research institutes, and state/federal laboratories. Activation Capital recently announced Virginia Gov. Glenn Youngkin awarded Activation Capital a $15 million portion of a total $66.7 million in grant funding for life sciences projects in the Commonwealth of Virginia.

Amy J. Broderick and Kate Hosko of Cushman & Wakefield | Thalhimer, along with David Thomann of Cushman & Wakefield’s Life Science Group in Boston, MA, have been awarded the exclusive leasing representation for the Innovation Center. Planned for delivery in late 2025, the center will feature approximately 35,000+ square feet of trophy class lab and creative office space for a lead tenant. Approximately 45,000 sf will be dedicated to an incubator operated by Activation Capital and will include shared labs, private offices, and community gathering spaces.  The new building will be located at the corner of 8th Street and Jackson Street.

“As part of our strategic plan to create a thriving ecosystem, Activation Capital will build an Innovation Center that anchors downtown Richmond’s innovation hub and serves as a magnet for innovators to build and grow deep tech companies. Once complete, the Innovation Center will catalyze downtown redevelopment around wealth-creating jobs, boost entrepreneurial growth, strengthen the region’s end-to-end pharmaceutical manufacturing cluster, and act as a platform for upskilling community members with STEM programming.,” said Chandra Briggman, President and CEO of Activation Capital

“In addition to their strong commercial real estate brokerage experience and national life science expertise, Cushman & Wakefield | Thalhimer was selected due to their alignment with Activation Capital’s values of agility, collaboration, entrepreneurial thinking, future-focus, impact, and inclusion,” said Kipton Currier, Vice President of Operations at Activation Capital. “The teams selected for the Innovation Center understand our commitment to the community, our excellence in execution focus, and our dedication to creating a nationally renowned life science innovation center for the benefit of future generations.”

Learn more here.

Recent News

10/11/2024

FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) approved ItovebiTM (inavolisib), in combination with palbociclib (Ibrance®) and fulvestrant, for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast

10/10/2024

RIVANNA initiates multi-site first-in-human study for Accuro XV musculoskeletal imaging system

RIVANNA®, developers of imaging-based medical solutions, has announced the launch of the first multi-site study employing the Accuro® XV musculoskeletal imaging system. This milestone follows a $30.5 million funding option executed in 2023 by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S.

10/09/2024

LifeNet Health’s Rapid Growth Continues with Acquisition of State-of-the-Art Virginia Beach Research Laboratory

A company that is a global leader in regenerative medicine has acquired a cutting-edge research laboratory in Virginia Beach. LifeNet Health will use the laboratory as a center of excellence for groundbreaking liver disease research and sports medicine applications. The dual function will provide better health solutions for a growing number of patients. Situated near